Bausch Health Companies Inc. (NYSE: BHC; TSX: BHC), through its gastroenterology business Salix Pharmaceuticals, has reported new real-world findings showing substantial mortality and hospital readmission among patients with severe alcohol-associated hepatitis. Announced on 6 November 2026 for presentation at the American Association for the Study of Liver Diseases’ The Liver Meeting in Denver, the study evaluated 1,630 US adults and estimated overall survival of 62.0% at 12 months.
The analysis also found that 31.4% of patients were rehospitalised within 30 days of discharge, with the estimated 12-month rehospitalisation rate reaching 69.1%. Liver transplantation occurred at an estimated rate of 8.5% over 12 months, reflecting the considerable clinical burden associated with a condition that can progress rapidly and require intensive medical management.
These findings extend the discussion beyond the immediate treatment of severe alcohol-associated hepatitis to the difficulty of maintaining clinical stability following hospitalisation. For healthcare systems, the combination of mortality, recurrent admissions and transplantation creates a significant demand for coordinated hepatology services, addiction treatment, post-discharge monitoring and specialist care.
The research also has strategic relevance for Salix, whose established gastroenterology and hepatology portfolio includes therapies for complications of advanced liver disease. However, the findings are observational and do not evaluate the effectiveness of any particular Salix medicine or establish that a new treatment strategy can improve the reported outcomes.
What does the 1,630-patient Salix study reveal about survival after severe alcohol-associated hepatitis?
The study, titled Clinical Burden and Outcomes in a Large Real-World Cohort of Patients Hospitalized with Severe Alcohol-Associated Hepatitis, examines outcomes among adults admitted to US hospitals with severe disease. It is identified as poster 3154 at The Liver Meeting 2026, taking place from 5 to 9 November.
According to Bausch Health, estimated overall survival at 12 months was 62.0%. This corresponds to an estimated cumulative mortality burden of approximately 38% over the same period, although the interpretation depends on the study’s survival methodology, follow-up completeness and patient characteristics.
The survival estimate is clinically consequential because severe alcohol-associated hepatitis can involve rapidly deteriorating liver function, systemic inflammation and complications affecting multiple organ systems. Patients may develop kidney injury, infections, hepatic encephalopathy and other complications that influence survival independently of the initial liver injury.
The company’s announcement does not provide a complete description of how patients were identified, the period during which they were hospitalised or the distribution of baseline disease severity. It also does not establish the proportion who had pre-existing cirrhosis, the treatments they received or how outcomes differed across clinically important subgroups.
These details are relevant when interpreting the estimates. A cohort containing large numbers of patients with advanced cirrhosis, kidney dysfunction or multiple previous hospitalisations may experience different outcomes from a population admitted earlier in the course of alcohol-associated liver disease.
Nevertheless, the reported survival figure provides a substantial indication of the clinical burden in the population studied. It also reinforces the need to distinguish discharge from hospital as an immediate milestone from sustained recovery over the following months.
Severe alcohol-associated hepatitis is not identical to cirrhosis, although the conditions frequently overlap. Alcohol-associated hepatitis refers to an acute inflammatory presentation associated with substantial alcohol exposure, while cirrhosis describes advanced chronic liver scarring. Patients can have both conditions, and the presence of underlying cirrhosis can affect prognosis and treatment requirements.
Why is the estimated 69.1% rehospitalisation rate particularly important for healthcare providers?
The readmission findings may be among the study’s most operationally significant observations. Salix reported that 31.4% of patients experienced rehospitalisation within 30 days of discharge, while the estimated cumulative rehospitalisation rate reached 69.1% by 12 months. These figures suggest a substantial burden of recurrent hospital care among the studied population.
Rehospitalisation can occur for several reasons following severe alcohol-associated hepatitis. Potential contributors include recurrent liver decompensation, infections, kidney dysfunction, gastrointestinal bleeding, fluid accumulation and other complications. Alcohol use disorder and the availability of ongoing medical and social support may also influence long-term outcomes.
The announcement does not disclose the specific causes of readmission or the proportion attributable directly to recurrent alcohol-associated hepatitis. Consequently, the reported rate cannot be used to determine which complication accounts for the greatest share of repeat hospitalisations.
From a health-system perspective, recurrent admissions can place considerable pressure on inpatient capacity, specialist services and emergency care resources. Patients with complicated liver disease may require coordinated management involving hepatologists, hospital physicians, addiction medicine specialists, dietitians and social workers.
The 30-day finding is particularly relevant because early readmission is frequently used as a healthcare quality and resource-utilisation measure. However, it should not automatically be interpreted as evidence of inadequate hospital care. Some readmissions may reflect the natural course of severe disease, while others may be influenced by differences in patient characteristics, discharge arrangements and access to follow-up care.
A more complete evaluation would need to distinguish planned from unplanned admissions, identify principal readmission diagnoses and account for death as a competing event. It would also be valuable to determine whether patients receiving coordinated post-discharge support experience different outcomes after adjustment for baseline risk.
The findings therefore identify an important population for further investigation rather than establishing the effectiveness of any particular hospital management model. Prospective research could assess whether structured follow-up, improved access to addiction treatment or more intensive monitoring produces measurable reductions in readmission and mortality.
How do the findings compare with established treatment challenges in severe alcohol-associated hepatitis?
The reported burden is consistent with the recognised seriousness of severe alcohol-associated hepatitis. The American College of Gastroenterology’s 2024 clinical guideline describes severe presentations as carrying substantial short-term mortality risk, particularly when accompanied by acute-on-chronic liver failure. The guideline also emphasises the importance of treating both liver disease and alcohol use disorder.
Current management includes careful assessment of disease severity, supportive medical care, nutritional evaluation, management of complications and treatment of alcohol use disorder. Corticosteroids may be considered in selected patients with severe disease, while their continued use depends on clinical response and safety considerations. Liver transplantation may be appropriate for carefully selected patients whose disease does not respond adequately to medical management.
These approaches address different components of a complex clinical condition. The presence of an established acute treatment does not necessarily eliminate longer-term risks, particularly when patients have advanced liver dysfunction or multiple underlying complications.
One challenge is that improvements in short-term outcomes may not translate directly into durable survival benefits. A patient may recover sufficiently to leave hospital but remain vulnerable to recurrent liver complications, infections or further deterioration. Evaluating treatment success therefore requires attention to follow-up periods extending beyond the initial admission.
The study’s 12-month survival and rehospitalisation findings provide useful context for these longer-term concerns. However, they do not demonstrate whether individual treatments were beneficial, ineffective or underutilised, because the company’s announcement does not describe the comparative treatment exposure needed for such conclusions.
Future research could examine whether specific discharge and follow-up strategies are associated with improved outcomes across clinically defined patient groups. Such work would need to account for baseline liver function, alcohol use disorder treatment, concurrent medical conditions and the availability of specialist services.
What does the 8.5% liver transplantation rate reveal about treatment pathways and access?
Salix reported an estimated liver transplantation rate of 8.5% at 12 months among the patients studied. This provides an indication of transplantation activity within the cohort, but it does not establish how many patients were eligible for transplantation or how many were assessed and declined.
Liver transplantation can be an important treatment option for selected patients with severe alcohol-associated hepatitis who do not respond adequately to medical therapy. Decisions concerning eligibility involve assessment of medical condition, expected benefit, psychosocial circumstances and the likelihood of sustained engagement with necessary follow-up care.
Not every patient with severe disease is an appropriate transplant candidate. Some patients may have contraindications, while others may improve with treatment or have clinical circumstances that make transplantation unsuitable. Access can also vary according to referral patterns, transplant-centre availability and local healthcare infrastructure.
Consequently, the observed transplantation rate should not be interpreted as evidence that 91.5% of patients were denied a beneficial intervention. The denominator includes patients with potentially different clinical trajectories, and the announcement provides insufficient information to establish unmet transplantation eligibility.
A more informative analysis would examine referral rates, eligibility assessments, waiting-list decisions, transplant timing and outcomes among patients who did and did not receive a transplant. Such information could help distinguish clinical constraints from potential service-access barriers.
The broader significance is that severe alcohol-associated hepatitis requires management decisions involving different levels of care. The transition from acute hospital treatment to specialist follow-up, addiction services and potential transplantation can be difficult for patients with complex medical and social circumstances.
The research adds to the rationale for studying these pathways systematically, although no causal conclusions about access or transplantation policy can be drawn from the disclosed figures alone.
Why does the research matter to Salix Pharmaceuticals’ wider liver disease strategy?
Salix Pharmaceuticals is an established specialty pharmaceutical business within Bausch Health, with commercial activities spanning gastroenterology and hepatology. Its principal medicine, Xifaxan, contains rifaximin and is approved in the United States for several specified indications, including reducing the risk of recurrence of overt hepatic encephalopathy in adults.
Hepatic encephalopathy is a complication associated with liver dysfunction and can affect cognition, behaviour and neurological function. Its management is relevant to advanced liver disease, but it is clinically distinct from treating the acute inflammatory process of severe alcohol-associated hepatitis.
Xifaxan is not approved specifically to treat severe alcohol-associated hepatitis or to prevent the mortality and rehospitalisation outcomes described in the new study. The observational findings should therefore not be presented as direct evidence supporting expanded use of the product.
The research instead demonstrates Salix’s continued engagement with the clinical and economic burden of advanced liver disease. Disease-burden studies can help identify unmet needs, refine research priorities and inform healthcare planning, particularly where treatment pathways involve repeated hospitalisation and substantial specialist resource use.
For pharmaceutical companies, observational datasets may also contribute to understanding how patients move through clinical care and where additional research could be valuable. They cannot replace controlled clinical trials when establishing the efficacy of a new medicine or an expanded indication.
Bausch Health’s chief medical officer and head of research and development, Jonathan Sadeh, characterised the findings as evidence of a substantial unmet need among patients hospitalised with severe alcohol-associated hepatitis. The company’s stated rationale is that real-world research can improve understanding of patient needs and support future research priorities.
That interpretation is reasonable within the limits of the data, but the announcement does not identify a new Salix investigational therapy for the condition or establish a regulatory development milestone arising from the study.
How do Bausch Health’s latest Salix financial results frame the commercial significance?
The research announcement follows a period of strong reported revenue growth for Bausch Health’s Salix segment. In its third-quarter 2026 financial results, released on 28 October, Bausch Health reported Salix revenue of US$831 million, up 16% from US$716 million a year earlier. Organic revenue growth was 14%.
Xifaxan remained the primary commercial contributor, accounting for approximately 85% of Salix segment revenue. The company reported that Xifaxan revenue increased 16% during the quarter, although the wider segment’s growth reflected important changes in realised pricing and product volume.
Bausch Health’s regulatory filing attributed US$152 million of the segment’s year-on-year revenue improvement to higher net realised pricing, partly offset by a US$50 million volume decline. This indicates that the headline revenue increase should not be interpreted simply as evidence of greater treatment demand.
The distinction matters when assessing the commercial relevance of disease-burden research. High rates of hospitalisation and substantial unmet clinical needs do not automatically translate into increased prescriptions or revenue for a company’s existing products. Commercial outcomes depend on approved indications, treatment eligibility, payer access and actual prescribing patterns.
At the group level, Bausch Health reported third-quarter consolidated revenue of US$2.94 billion, representing 10% reported growth. It also announced higher full-year guidance and improved cash generation within the business excluding Bausch + Lomb.
The company’s recent financial performance provides context for its capacity to support research and commercial operations. However, the severe alcohol-associated hepatitis poster is not a drug approval, an efficacy study or a new revenue-generating product announcement.
How have Bausch Health shares performed as investors assess its gastroenterology business?
Bausch Health’s New York-listed shares closed at US$7.96 on 5 November 2026, declining 4.56% from the preceding session. The stock had traded between approximately US$4.33 and US$9.04 over the previous 52 weeks, indicating a substantial valuation range during the period.
The shares experienced marked volatility following the company’s October financial results, including a sharp advance around the earnings announcement and subsequent pullback. These movements reflect a broader investment context involving operating performance, debt management, valuation and expectations for the company’s pharmaceutical portfolio.
The Salix research disclosure is unlikely to constitute an immediate financial catalyst of comparable magnitude because it does not announce an approved medicine, material commercial agreement or new clinical efficacy result. Its significance is principally scientific and strategic, highlighting the burden of serious liver disease within a therapeutic area relevant to the company’s existing operations.
Investors assessing Bausch Health will continue to focus on the performance of Xifaxan, the durability of Salix revenue, pricing dynamics, debt reduction and the group’s capacity to generate cash. Disease-burden research may support longer-term clinical strategy, but its value cannot be translated directly into product sales.
What evidence is needed before the findings can influence routine liver disease management?
The next analytical step is a fuller assessment of the study’s methodology and the factors associated with mortality, rehospitalisation and transplantation. Information about baseline disease severity, existing cirrhosis, prior hospitalisations, treatment exposure and causes of readmission would help clinicians interpret the results more precisely.
It would also be useful to examine how outcomes vary over time. Patients rehospitalised soon after discharge may differ clinically from those experiencing complications several months later. Understanding these patterns could help researchers identify which management questions deserve prospective investigation.
For healthcare providers, the study strengthens the case for evaluating integrated post-discharge care for patients with severe alcohol-associated hepatitis. However, any claims that a particular programme reduces mortality or hospital use would require comparative evidence, ideally from appropriately designed prospective studies.
The findings presented at The Liver Meeting 2026 are conference-level observational evidence. Their interpretation may evolve as additional methods, subgroup analyses and peer-reviewed publications become available.
For Salix, the study contributes to understanding the substantial healthcare burden surrounding advanced alcohol-associated liver disease without extending the approved use of its existing medicines. Its most consequential contribution may be helping define research questions that connect acute hospital treatment with sustained recovery. The reported 62% one-year survival and 69.1% estimated rehospitalisation rate establish the scale of the problem in this cohort; determining which interventions can reliably improve those outcomes remains the central clinical challenge.
